{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T02:21:54Z","timestamp":1715998914964},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.beha.2011.03.007","type":"journal-article","created":{"date-parts":[[2011,5,18]],"date-time":"2011-05-18T04:34:44Z","timestamp":1305693284000},"page":"295-304","source":"Crossref","is-referenced-by-count":6,"title":["Translational development of vaccination strategies in follicular NHL"],"prefix":"10.1016","volume":"24","author":[{"given":"Ippei","family":"Sakamaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry W.","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2011.03.007_bib1","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1073\/pnas.69.6.1540","article-title":"Myeloma proteins as tumor-specific transplantation antigens","volume":"69","author":"Lynch","year":"1972","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.beha.2011.03.007_bib2","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1084\/jem.140.6.1547","article-title":"Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB\/NZW F1 mice","volume":"140","author":"Sugai","year":"1974","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.beha.2011.03.007_bib3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/jnci\/56.4.735","article-title":"Tumor immunity induced by preimmunization with BALB\/c mouse myeloma protein","volume":"56","author":"Freedman","year":"1976","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.beha.2011.03.007_bib4","first-page":"2268","article-title":"Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target","volume":"36","author":"Stevenson","year":"1977","journal-title":"Fed Proc."},{"key":"10.1016\/j.beha.2011.03.007_bib5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.4049\/jimmunol.121.2.479","article-title":"Participation of the humoral immune system in the myeloma-specific transplantation resistance","volume":"121","author":"Bridges","year":"1978","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.beha.2011.03.007_bib6","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.4049\/jimmunol.120.5.1620","article-title":"Idiotype-specific transplantation resistance to MOPC-315: abrogation by post-immunization thymectomy","volume":"120","author":"Daley","year":"1978","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.beha.2011.03.007_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-3083.1980.tb00205.x","article-title":"Immunization with the light chain and the VL domain of the isologous myeloma protein 315 inhibits growth of mouse plasmacytoma MOPC315","volume":"11","author":"J\u00f8rgensen","year":"2006","journal-title":"Scandinavian Journal of Immunology"},{"key":"10.1016\/j.beha.2011.03.007_bib8","doi-asserted-by":"crossref","first-page":"970","DOI":"10.4049\/jimmunol.130.2.970","article-title":"Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation","volume":"130","author":"Stevenson","year":"1983","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.beha.2011.03.007_bib9","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4049\/jimmunol.138.2.628","article-title":"Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1","volume":"138","author":"George","year":"1987","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.beha.2011.03.007_bib10","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.4049\/jimmunol.138.4.1289","article-title":"Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein","volume":"138","author":"Kaminski","year":"1987","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.beha.2011.03.007_bib11","doi-asserted-by":"crossref","first-page":"10972","DOI":"10.1073\/pnas.93.20.10972","article-title":"Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte\/macrophage colony-stimulating factor primes mice for a protective T-cell response","volume":"93","author":"Kwak","year":"1996","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.beha.2011.03.007_bib12","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJM199210223271705","article-title":"Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors","volume":"327","author":"Kwak","year":"1992","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beha.2011.03.007_bib13","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood.V89.9.3129","article-title":"Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma\u2013long-term results of a clinical trial","volume":"89","author":"Hsu","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.007_bib14","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/13928","article-title":"Complete molecular remissions induced by patient-specific vaccination plus granulocyte\u2013monocyte colony-stimulating factor against lymphoma","volume":"5","author":"Bendandi","year":"1999","journal-title":"Nature Medicine"},{"key":"10.1016\/j.beha.2011.03.007_bib15","doi-asserted-by":"crossref","first-page":"10131","DOI":"10.1073\/pnas.0803636105","article-title":"Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study","volume":"105","author":"McCormick","year":"2008","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.beha.2011.03.007_bib16","first-page":"400","article-title":"Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma","volume":"87","author":"Barrios","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2011.03.007_bib17","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/jnci\/djj358","article-title":"Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma","volume":"98","author":"Inoges","year":"2006","journal-title":"JNCI Journal of the National Cancer Institute"},{"key":"10.1016\/j.beha.2011.03.007_bib18","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.1182\/blood-2009-01-201988","article-title":"Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma","volume":"113","author":"Ai","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.007_bib19","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.2008.19.8903","article-title":"Placebo-Controlled phase III trial of patient-specific immunotherapy with Mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma","volume":"27","author":"Freedman","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2011.03.007_bib20","first-page":"19","article-title":"Results of a phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymphoma (fNHL)","author":"Levy","year":"2008","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.beha.2011.03.007_bib21","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Neelapu SS, Gause BL, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. Journal of Clinical Oncology. 2011, In Press.","DOI":"10.1200\/JCO.2010.33.3005"},{"key":"10.1016\/j.beha.2011.03.007_bib22","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.007_bib23","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/nm1290","article-title":"Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma","volume":"11","author":"Neelapu","year":"2005","journal-title":"Nature Medicine"},{"key":"10.1016\/j.beha.2011.03.007_bib24","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/nm0996-1038","article-title":"DNA immunization induces protective immunity against B-cell lymphoma","volume":"2","author":"Syrengelas","year":"1996","journal-title":"Nature Medicine"},{"key":"10.1016\/j.beha.2011.03.007_bib25","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.4049\/jimmunol.157.12.5503","article-title":"A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines","volume":"157","author":"Hakim","year":"1996","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.beha.2011.03.007_bib26","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.4049\/jimmunol.159.4.1885","article-title":"DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C","volume":"159","author":"Spellerberg","year":"1997","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.beha.2011.03.007_bib27","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/3266","article-title":"DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma","volume":"4","author":"King","year":"1998","journal-title":"Nature Medicine"},{"key":"10.1016\/j.beha.2011.03.007_bib28","first-page":"5845","article-title":"Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma","volume":"62","author":"Timmerman","year":"2002","journal-title":"Cancer Research"},{"key":"10.1016\/j.beha.2011.03.007_bib29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/6995","article-title":"Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity","volume":"17","author":"Biragyn","year":"1999","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.beha.2011.03.007_bib30","doi-asserted-by":"crossref","first-page":"6644","DOI":"10.4049\/jimmunol.167.11.6644","article-title":"Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens","volume":"167","author":"Biragyn","year":"2001","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.beha.2011.03.007_bib31","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1182\/blood-2009-05-219683","article-title":"Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity","volume":"114","author":"Qin","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.007_bib32","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.4049\/jimmunol.160.8.3637","article-title":"Cutting edge: liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity","volume":"160","author":"Kwak","year":"1998","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.beha.2011.03.007_bib33","doi-asserted-by":"crossref","first-page":"8309","DOI":"10.1158\/1078-0432.CCR-04-1071","article-title":"Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen","volume":"10","author":"Neelapu","year":"2004","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.beha.2011.03.007_bib34","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1182\/blood-2006-12-063594","article-title":"A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma","volume":"109","author":"Neelapu","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.007_bib35","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nm0196-52","article-title":"Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells","volume":"2","author":"Hsu","year":"1996","journal-title":"Nature Medicine"},{"key":"10.1016\/j.beha.2011.03.007_bib36","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.V99.5.1517","article-title":"Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients","volume":"99","author":"Timmerman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.007_bib37","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.007_bib38","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","article-title":"Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.007_bib39","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/0008-5472.CAN-06-2317","article-title":"Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells","volume":"67","author":"Verhelle","year":"2007","journal-title":"Cancer Research"},{"key":"10.1016\/j.beha.2011.03.007_bib40","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/BF03401909","article-title":"Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity","volume":"2","author":"Corral","year":"1996","journal-title":"Molecular Medicine"},{"key":"10.1016\/j.beha.2011.03.007_bib41","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-{alpha}","volume":"163","author":"Corral","year":"1999","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.beha.2011.03.007_bib42","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.007_bib43","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1016\/j.beha.2011.03.007_bib44","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.4049\/jimmunol.168.10.4914","article-title":"Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity","volume":"168","author":"Dredge","year":"2002","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.beha.2011.03.007_bib45","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.4049\/jimmunol.161.6.3042","article-title":"Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA","volume":"161","author":"Jakob","year":"1998","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.beha.2011.03.007_bib46","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1182\/blood.V92.10.3730","article-title":"Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor","volume":"92","author":"Liu","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.007_bib47","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8","article-title":"Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells","volume":"28","author":"Sparwasser","year":"1998","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.beha.2011.03.007_bib48","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.4049\/jimmunol.179.4.2493","article-title":"Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself","volume":"179","author":"Li","year":"2007","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.beha.2011.03.007_bib49","doi-asserted-by":"crossref","first-page":"9793","DOI":"10.1200\/JCO.2010.28.9793","article-title":"In situ vaccination with a TLR9 Agonist induces systemic lymphoma regression: a phase I\/II study","volume":"28","author":"Brody","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2011.03.007_bib50","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1182\/blood-2008-07-170274","article-title":"T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy","volume":"113","author":"Houot","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.007_bib51","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1182\/blood-2004-02-0762","article-title":"Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome","volume":"104","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.007_bib52","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.humpath.2005.08.005","article-title":"BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders","volume":"36","author":"Rodig","year":"2005","journal-title":"Human Pathology"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169261100034X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169261100034X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T20:39:07Z","timestamp":1686083947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169261100034X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S152169261100034X"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2011.03.007","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}